Danaher Beats Q2 Revenue and Earnings Estimates

Key Facts

1Danaher reported Q2 2026 revenue of $6.26 billion, exceeding expectations with 5.5% year-over-year growth.

2Adjusted earnings per share reached $1.94, beating the consensus analyst estimate of $1.85.

3The company expects full-year 2026 adjusted diluted EPS to range between $8.45 and $8.60.

Danaher Corporation reported Q2 2026 revenue of $6.26 billion, exceeding expectations with 5.5% year-over-year growth. Adjusted earnings per share reached $1.94, beating the consensus analyst estimate of $1.85, while the company said in a statement it expects full-year 2026 adjusted diluted EPS to range between $8.45 and $8.60.

DHR closed at $214.06 on October 2, 2026, prior to RBC Capital raising its price target for the stock to $250 from $215 with a maintained Outperform rating. The performance was bolstered by improving bioprocessing orders despite restrained diagnostics growth, bringing the average analyst price target to $234.09.

Danaher is scheduled to report its third-quarter 2026 financial results on October 21, 2026, as investors monitor the trajectory of core revenue growth which is projected to reach 3% to 4% for the full year.